Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SRRK 
Scholar Rock Holding Corp (SRRK)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SRRK (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 132.4% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.85B USD | Price to earnings Ratio - | 1Y Target Price 50.5 |
Price to earnings Ratio - | 1Y Target Price 50.5 | ||
Volume (30-day avg) 1066178 | Beta 0.6 | 52 Weeks Range 6.76 - 46.98 | Updated Date 04/1/2025 |
52 Weeks Range 6.76 - 46.98 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.47 |
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.6288 | Actual -0.61 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.09% | Return on Equity (TTM) -82.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2473831424 | Price to Sales(TTM) 13.14 |
Enterprise Value 2473831424 | Price to Sales(TTM) 13.14 | ||
Enterprise Value to Revenue 8.22 | Enterprise Value to EBITDA -2.08 | Shares Outstanding 94676800 | Shares Floating 69786242 |
Shares Outstanding 94676800 | Shares Floating 69786242 | ||
Percent Insiders 1.28 | Percent Institutions 116.69 |
Analyst Ratings
Rating 4.56 | Target Price 46.38 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Scholar Rock Holding Corp
Company Overview
History and Background
Scholar Rock was founded in 2012, focusing on discovering and developing medicines for the treatment of serious diseases in which signaling by protein growth factors plays a key role.
Core Business Areas
- Drug Discovery and Development: Focuses on developing therapeutics targeting growth factor activation in diseases such as spinal muscular atrophy (SMA), fibrosis, and cancer.
Leadership and Structure
The leadership team includes individuals with experience in drug development and biotechnology. The organizational structure is typical of a biotech company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Apitegromab: A selective inhibitor of myostatin activation, aimed at improving motor function in non-ambulatory patients with SMA. Apitegromab does not currently have market share as it is still in clinical trials. Competitors targeting SMA include Biogen (SPINRAZA), Novartis (ZOLGENSMA), and Roche (EVRYSDI).
- SRK-181: An inhibitor of latent TGFu03b21 activation designed to enhance the efficacy of checkpoint inhibitors in cancer immunotherapy. SRK-181 does not currently have market share as it is still in clinical trials. Competitors in cancer immunotherapy include Merck (KEYTRUDA), Bristol-Myers Squibb (OPDIVO), and Roche (TECENTRIQ).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The SMA and oncology markets are significant and growing.
Positioning
Scholar Rock is positioned as a company focused on growth factor inhibition to address unmet medical needs in SMA, fibrosis, and cancer. Their competitive advantage lies in their specific targeting mechanisms.
Total Addressable Market (TAM)
The total addressable market for SMA and oncology therapies is substantial, estimated to be in the tens of billions of dollars annually. Scholar Rock's position depends on successful clinical trials and market approval of their drug candidates.
Upturn SWOT Analysis
Strengths
- Novel approach to growth factor inhibition
- Strong intellectual property portfolio
- Experienced management team
- Targeting unmet medical needs
Weaknesses
- Dependence on clinical trial success
- High cash burn rate
- No products currently on the market
- Competition from established pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Accelerated regulatory approval pathways
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other emerging therapies
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- RHHBY
- MRK
- BMY
- LLY
Competitive Landscape
Scholar Rock is a smaller player competing with larger, established pharmaceutical companies. Their advantage lies in their novel approach, but their disadvantage is their limited resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by pipeline development and strategic partnerships.
Future Projections: Future growth depends on positive clinical trial data and regulatory approvals. Analyst estimates vary widely, reflecting the inherent uncertainty in biotech investments.
Recent Initiatives: Recent initiatives include advancing apitegromab in SMA and SRK-181 in oncology through clinical trials.
Summary
Scholar Rock is a clinical-stage biopharmaceutical company with a novel approach to growth factor inhibition, but is highly dependent on the success of its clinical trials. Its strengths include a strong IP portfolio and experienced management team. Potential threats include clinical trial failures and competition from large pharmaceutical companies. Overall, the company shows promise, but carries a high degree of risk.
Similar Companies
BIIB
Biogen Inc
BIIB
Biogen Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Scholar Rock Holding Corp. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise. Future outcomes are not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scholar Rock Holding Corp
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2018-05-24 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.scholarrock.com |
Full time employees 128 | Website https://www.scholarrock.com | ||
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.